William G. Wierda

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 40 papers. Top paper: “Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors”.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

New England Journal of Medicine(2020)10.1056/nejmoa1910607

N/A

5.4DataRank · unranked

2164 citations

David Marín, Pinaki P. Banerjee, Homer A. Macapinlac, Philip A. Thompson, Rafet Başar +22 more

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2856

N/A

4.5DataRank · unranked

184 citations

Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +9 more

Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

Nature Medicine(2023)10.1038/s41591-022-02113-6

N/A

1.7DataRank · unranked

83 citations

Ignaty Leshchiner, Romain Guièze, Connor Johnson, Eugen Tausch, Sameer A. Parikh +49 more

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2024)10.1182/bloodadvances.2023012231

N/A

0.940DataRank · unranked

34 citations

Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Fadi Haddad +18 more

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Blood(2024)10.1182/blood.2024024510

N/A

0.874DataRank · unranked

27 citations

Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda +13 more

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood(2025)10.1182/blood.2024024476

N/A

0.710DataRank · unranked

42 citations

Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn +22 more

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00675-9

N/A

0.617DataRank · unranked

60 citations

Görkem Kısmalı, LaKesla R. Iles, Ganiraju C. Manyam, Mary Ayres, Lisa S. Chen +5 more

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia

Blood(2025)10.1182/blood.2024027009

N/A

0.452DataRank · unranked

6 citations

Bastien Nguyen, Sai Prasad Desikan, Helen Won, Shady I. Tantawy, Samuel McNeely +22 more

Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2088

N/A

0DataRank · unranked

27 citations

Aloke Sarkar, Stefan Hübner, Zhi Tan, William G. Wierda, Abdelraouf Eldeib +4 more

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

American Journal of Hematology(2022)10.1002/ajh.26595

N/A

0DataRank · unranked

14 citations

Raamis Khwaja, Rashmi Kanagal‐Shamanna, Guilin Tang, Jan A. Burger, Philip A. Thompson +10 more

ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

Cancer Cell(2023)10.1016/j.ccell.2023.08.013

N/A

0DataRank · unranked

73 citations

Camilla K. Lemvigh, Stephanie L. Deng, Nathan Dangle, Neil Ruthen, Binyamin A. Knisbacher +30 more

Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.04.006

N/A

0DataRank · unranked

13 citations

Sairah Ahmed, Sheeba K. Thomas, Lan Sun Wang, Khalis Mustafayev, Luis Fayad +4 more

Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children’s Oncology Group

International Journal of Molecular Sciences(2023)10.3390/ijms24065460

N/A

0DataRank · unranked

2 citations

Ti’ara L. Griffen, Brandon D. Brown, Terzah M. Horton, Jan A. Burger, William G. Wierda +4 more

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Blood(2023)10.1182/blood-2023-187128

N/A

0DataRank · unranked

39 citations

William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan +6 more

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Blood(2023)10.1182/blood-2023-182568

N/A

0DataRank · unranked

1 citations

James D’Olimpio, Andew gillis-Smith, Seung‐Tae Lee, Nirav N. Shah, Javier Pinilla‐Ibarz +9 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood(2023)10.1182/blood-2023-190712

N/A

0DataRank · unranked

1 citations

David Harris, Uri Rozovski, Ping Li, Zhiming Liu, Taghi Manshouri +15 more

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood(2023)10.1182/blood-2023-190400

N/A

0DataRank · unranked

1 citations

Zongrui Li, Abhishek Maiti, Tomoyuki Tanaka, Hidetaka Uryu, Ken Furudate +21 more

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

Blood(2023)10.1182/blood-2023-189378

N/A

0DataRank · unranked

1 citations

John R. Sanchez, Chaomei Liu, Bailey Slawin, Nitin Jain, William G. Wierda +6 more

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Blood(2023)10.1182/blood-2023-186145

N/A

0DataRank · unranked

0 citations

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel +17 more

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Blood(2023)10.1182/blood-2023-180230

N/A

0DataRank · unranked

0 citations

Sahar Ansari, Jason Wall, Ethan Thompson, Yizhe Chen, Tanya Siddiqi +6 more

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood(2023)10.1182/blood-2023-173992

N/A

0DataRank · unranked

0 citations

Ted Gooley, Tanya Siddiqi, Deborah M. Stephens, Catherine M. Broome, Stephen E. Spurgeon +18 more

The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia

Blood Cancer Journal(2024)10.1038/s41408-024-01142-3

N/A

0DataRank · unranked

11 citations

Priyanka Khare, Priyanka Banerjee, Cristina Ivan, Sarah Schneider, Federica Barbaglio +20 more

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica(2024)10.3324/haematol.2024.285754

N/A

0DataRank · unranked

13 citations

Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda +30 more

Artificial Intelligence Assessment of Chest Radiographs for COVID-19

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.013

N/A

0DataRank · unranked

2 citations

Guillermo Garcia‐Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G. Wierda +14 more

Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels

Blood Cancer Journal(2024)10.1038/s41408-024-01196-3

N/A

0DataRank · unranked

1 citations

Ganiraju C. Manyam, Nitin Jain, Cristina Ivan, Betty Lamothe, Mary Ayres +4 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood(2025)10.1182/blood.2024028064

N/A

0DataRank · unranked

16 citations

Monia Marchetti, Othman Al‐Sawaf, Ohad Benjamini, Alexey V. Danilov, Matthew S. Davids +24 more

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression

Blood Cancer Journal(2025)10.1038/s41408-025-01382-x

N/A

0DataRank · unranked

2 citations

Burcu Aslan, Ganiraju C. Manyam, LaKesla R. Iles, Natalia Timofeeva, Neetu Singh +8 more

Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia

Blood(2025)10.1182/blood.2025028570

N/A

0DataRank · unranked

2 citations

Barbara Eichhorst, Michael Hallek, William G. Wierda

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

Developing MRD as an early endpoint for accelerated approval in CLL

Seminars in Hematology(2025)10.1053/j.seminhematol.2026.03.008

N/A

0DataRank · unranked

1 citations

William G. Wierda, Jacob D. Soumerai

Clinical value of event-free survival in acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001150

N/A

0DataRank · unranked

7 citations

Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva +16 more

Gene Therapy: Charting a Future Course—Summary of a National Institutes of Health Workshop, April 12, 2013

UNC Libraries(2020)10.17615/bazj-3394

N/A

0DataRank · unranked

0 citations

Howard J. Federoff, Luk H. Vandenberghe, Aravind Asokan, Mehrdad Abedi, Laurie Zoloth +27 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

The cure of leukemia through the optimist's prism

Cancer(2021)10.1002/cncr.33933

N/A

0DataRank · unranked

67 citations

Nitin Jain, Guillermo Garcia‐Manero, Mary Alma Welch, Farhad Ravandi, William G. Wierda +2 more

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Blood(2021)10.1182/blood.2021012315

N/A

0DataRank · unranked

24 citations

Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson +4 more

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

Haematologica(2021)10.3324/haematol.2021.279158

N/A

0DataRank · unranked

22 citations

Stefan Hübner, Judith A. Fox, Pietro Taverna, William G. Wierda, Steven M. Kornblau +2 more

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells

Oncotarget(2021)10.18632/oncotarget.27884

N/A

0DataRank · unranked

11 citations

David Harris, Ping Li, Zhiming Liu, Preetesh Jain, Taghi Manshouri +10 more